IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
Yao, L.1; Liu, Y.2; Li, Z.1; Ouyang, T.1; Li, J.1; Wang, T.1; Fan, Z.1; Fan, T.1; Lin, B.1; Xie, Y.1
关键词anthracycline breast cancer HER2 neoadjuvant chemotherapy
刊名ANNALS OF ONCOLOGY
2011-06-01
DOI10.1093/annonc/mdq612
22期:6页:1326-1331
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]SURGICAL ADJUVANT BREAST ; PREOPERATIVE CHEMOTHERAPY ; SYSTEMIC THERAPY ; RANDOMIZED-TRIALS ; DOXORUBICIN ; WOMEN ; DOCETAXEL ; CYCLOPHOSPHAMIDE ; SENSITIVITY ; EXPRESSION
英文摘要

Background: The predictive role of human epidermal growth factor receptor 2 (HER2) to adjuvant anthracycline-based chemotherapy remains controversial. Here, we investigated the association between HER2 status and pathological response in breast cancer patients who received neoadjuvant anthracycline-based regimens.

Patients and methods: Women (n = 538) with operable primary breast cancer received neoadjuvant anthracycline-based chemotherapy. Pathological complete response (pCR) was defined as no invasive breast tumor cells in breast after completion of neoadjuvant chemotherapy. HER2 status was determined by immunohistochemistry and/or by fluorescence in situ hybridization in core biopsy breast cancer tissue obtained before initiation of neoadjuvant chemotherapy.

Results: In this cohort of 538 patients, 23.9% of patients achieved a pCR in their breast. HER2-positive tumors had a lower rate of pCR than did HER2-negative tumors (14.7% versus 25.7%, P = 0.013); negative HER2 status remained as an independent favorable predictor of pCR after adjusted for age, estrogen receptor, progesterone receptor, tumor size, chemotherapy cycles, and tumor grade in a multivariate analysis (odds ratio = 3.14; 95% confidence interval = 1.60-6.16, P = 0.001). Furthermore, patients with a pCR had a higher 3-year disease-free survival (DFS) rate than did patients without a pCR (P = 0.007).

Conclusion: Women with HER2-negative breast cancers rather than HER2-positive tumors benefit from anthracycline-based neoadjuvant chemotherapy.

语种英语
WOS记录号WOS:000291060800012
引用统计
被引频次:13[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62330
专题北京大学临床肿瘤学院
北京大学公共卫生学院_公共卫生学院
北京大学临床肿瘤学院_乳腺癌预防治疗中心
北京大学临床肿瘤学院_乳腺中心实验室
作者单位1.Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst, Breast Ctr, Beijing 100142, Peoples R China
2.Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst,Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Yao, L.,Liu, Y.,Li, Z.,et al. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer[J]. ANNALS OF ONCOLOGY,2011,22(6):1326-1331.
APA Yao, L..,Liu, Y..,Li, Z..,Ouyang, T..,Li, J..,...&Xie, Y..(2011).HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.ANNALS OF ONCOLOGY,22(6),1326-1331.
MLA Yao, L.,et al."HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer".ANNALS OF ONCOLOGY 22.6(2011):1326-1331.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yao, L.]的文章
[Liu, Y.]的文章
[Li, Z.]的文章
百度学术
百度学术中相似的文章
[Yao, L.]的文章
[Liu, Y.]的文章
[Li, Z.]的文章
必应学术
必应学术中相似的文章
[Yao, L.]的文章
[Liu, Y.]的文章
[Li, Z.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。